

Axsome Therapeutics, Inc. (AXSM)


Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001579428

Axsome Therapeutics, Inc. AXSM; healthcare	
Grade	A/B A B C D E on the A/B boundary of 371 graded peers percentile 21.4; sampling error 2.5 points; lower is stronger
Rank	80 of 371
Profitability	B percentile 31.7
Solvency	D percentile 64.4
Growth and financing	A/B percentile 21.4
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$689.8M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 23, 2026 228 days before the rescans; latest periodic filing 10-Q received Aug 10, 2026
Last close	\$170.26 2026-10-08; market equity \$8.9B
Price used in grade	None



A/B, the bull
on the A/B boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 23, 2026

We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes. Our innovative CNS portfolio is anchored by three U.S.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 31.7						
Gross profitability		not computable	32.2%			latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(14.3%)	(6.6%)	31.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 64.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(5.64)	(0.31)	53.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		(10.47x)	(4.51x)	60.0	81	2025-12-31
Current ratio		1.55x	2.96x	79.4	839	2025-12-31
Growth and financing, sleeve percentile 21.4						
Revenue growth, three-year compound		133.7%	10.0%	3.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		27.7%	2.1%	16.5	704	2025-12-31
Net share issuance, one year		4.9%	2.5%	44.7	634	2026-02-16

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
75	Ocular Therapeutix, Inc. (OCUL)	20.0	A/B	dilution
76	Boston Scientific Corp. (BSX)	20.3	A/B	
77	Siga Technologies Inc. (SIGA)	20.5	A/B	fortress
78	West Pharmaceutical Services Inc. (WST)	20.8	A/B	balance sheet fortress
79	Rigel Pharmaceuticals Inc. (RIGL)	21.1	A/B	balance sheet
80	Axsome Therapeutics, Inc. (AXSM) <	21.4	A/B	
81	Axogen, Inc. (AXGN)	21.6	A/B	
82	Halozyme Therapeutics, Inc. (HALO)	21.9	A/B	
83	4D Molecular Therapeutics, Inc. (FDMT)	22.2	A/B	dilution, short runway
84	Rhythm Pharmaceuticals, Inc. (RYTM)	22.4	A/B	
85	Puma Biotechnology, Inc. (PBYI)	22.7	B	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	63.5%	8.0%	81
Distance from 52-week high	(33.3%)	(31.4%)	46
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(1.1%)	(1.0%)	49
Book value to price	0.01	0.28	13
Sales to price	0.07	0.31	20
Composite equity issuance, five years	33.7%	20.3%	60
Relative strength against the sector, log excess return	0.28	(0.14)	81

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$319.9M
Operating cash flow, four quarters	-\$71.3M

Months of runway	53.9
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$141.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$50.0M	2022-12-31	2025-02-18	10-K	0000950170-25-022457
2	cost of revenue	us-gaap:CostOfRevenue	\$5.2M	2022-12-31	2023-02-28	10-K	0000950170-23-004728
3	assets	us-gaap:Assets	\$331.5M	2022-12-31	2024-02-23	10-K	0000950170-24-019118
4	net income	us-gaap:NetIncomeLoss	-\$183.2M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$93.4M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
6	assets	us-gaap:Assets	\$689.8M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
7	assets	us-gaap:Assets	\$568.5M	2024-12-31	2026-02-23	10-K	0001193125-26-064267
8	current assets	us-gaap:AssetsCurrent	\$589.0M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
9	current liabilities	us-gaap:LiabilitiesCurrent	\$378.8M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.3B	2025-12-31	2026-02-23	10-K	0001193125-26-064267
11	operating income	us-gaap:OperatingIncomeLoss	-\$166.8M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
12	book equity	us-gaap:StockholdersEquity	\$88.3M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
13	liabilities	us-gaap:Liabilities	\$601.5M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
14	interest expense	us-gaap:InterestExpense	-\$15.9M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$638.5M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$385.7M	2024-12-31	2026-02-23	10-K	0001193125-26-064267
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$270.6M	2023-12-31	2026-02-23	10-K	0001193125-26-064267
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$480,000	2025-12-31	2026-02-23	10-K	0001193125-26-064267
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$128.4M	2024-12-31	2026-02-23	10-K	0001193125-26-064267
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$270,000	2024-12-31	2026-02-23	10-K	0001193125-26-064267
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$145.1M	2023-12-31	2026-02-23	10-K	0001193125-26-064267
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$582,000	2023-12-31	2026-02-23	10-K	0001193125-26-064267
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$116.5M	2022-12-31	2025-02-18	10-K	0000950170-25-022457
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$702,000	2022-12-31	2025-02-18	10-K	0000950170-25-022457
25	depreciation amortization	us-gaap:Depreciation	\$503,000	2025-12-31	2026-02-23	10-K	0001193125-26-064267
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$188.7M	2025-12-31	2026-02-23	10-K	0001193125-26-064267
27	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$530,000	2025-12-31	2026-02-23	10-K	0001193125-26-064267
28	current assets	us-gaap:AssetsCurrent	\$485.1M	2024-12-31	2026-02-23	10-K	0001193125-26-064267
29	current liabilities	us-gaap:LiabilitiesCurrent	\$230.1M	2024-12-31	2026-02-23	10-K	0001193125-26-064267
30	assets	us-gaap:Assets	\$588.2M	2023-12-31	2025-02-18	10-K	0000950170-25-022457
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,153,289	2026-02-16	2026-02-23	10-K	0001193125-26-064267
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	48,765,403	2025-02-11	2025-02-18	10-K	0000950170-25-022457